Skip to main content
SpringerLink
Log in

An Unusual Case of Acute Liver Failure Caused by Adjuvant Oral Tegafur-Uracil with Folinate Therapy for Colon Cancer Patient: a Case Report

  • Case Report
  • Published:
Journal of Gastrointestinal Cancer Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

References

  1. Zimmerman HJ. Drug-induced liver disease. Clin Liver Dis. 2000;4:73–96 vi.

    Article  CAS  Google Scholar 

  2. Leise MD, Poterucha JJ, Talwalkar JA. Drug-induced liver injury. Mayo Clin Proc. 2014;89:95–106.

    Article  CAS  Google Scholar 

  3. Takikawa H, Murata Y, Horiike N, Fukui H, Onji M. Drug-induced liver injury in Japan: an analysis of 1676 cases between 1997 and 2006. Hepatol Res. 2009;39:427–31.

    Article  Google Scholar 

  4. Watanabe T, Muro K, Ajioka Y, Hashiguchi Y, Ito Y, Saito Y, et al. Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer. Int J Clin Oncol. 2018;23:1–34.

    Article  Google Scholar 

  5. Tashiro J, Yamaguchi S, Ishii T, Kondo H, Hara K, Shimizu H, et al. Oncologic outcomes of oral adjuvant chemotherapy regimens in stage III colon cancer: tegafur-uracil plus leucovorin versus capecitabine. Clin Colorectal Cancer. 2017;16:e141–e5.

    Article  Google Scholar 

  6. Tsuchiya T, Sadahiro S, Sasaki K, Kondo K, Katsumata K, Nishimura G, et al. Safety analysis of two different regimens of uracil-tegafur plus leucovorin as adjuvant chemotherapy for high-risk stage II and III colon cancer in a phase III trial comparing 6 with 18 months of treatment: JFMC33-0502 trial. Cancer Chemother Pharmacol. 2014;73:1253–61.

    Article  CAS  Google Scholar 

  7. Shirao K, Hoff PM, Ohtsu A, Loehrer PJ, Hyodo I, Wadler S, et al. Comparison of the efficacy, toxicity, and pharmacokinetics of a uracil/tegafur (UFT) plus oral leucovorin (LV) regimen between Japanese and American patients with advanced colorectal cancer: joint United States and Japan study of UFT/LV. J Clin Oncol. 2004;22:3466–74.

    Article  CAS  Google Scholar 

  8. Brierley J, Gospodarowicz M, Wittekind CTNM. Classification of malignant tumours. 8th ed: Wiley-Blackwell; 2016.

  9. Kamath PS, Wiesner RH, Malinchoc M, Kremers W, Therneau TM, Kosberg CL, et al. A model to predict survival in patients with end-stage liver disease. Hepatology. 2001;33:464–70.

    Article  CAS  Google Scholar 

  10. Toide H, Akiyoshi H, Minato Y, Okuda H, Fujii S. Comparative studies on the metabolism of 2-(tetrahydrofuryl)-5-fluorouracil and 5-fluorouracil. Gan. 1977;68:553–60.

    CAS  PubMed  Google Scholar 

  11. Gonzalez-Baron M, Feliu J, de la Gandara I, Espinosa E, Colmenarejo A, Martinez-Martinez B, et al. Efficacy of oral tegafur modulation by uracil and leucovorin in advanced colorectal cancer. A phase II study. Eur J Cancer. 1995;31A:2215–9.

    Article  CAS  Google Scholar 

  12. Shimada Y, Hamaguchi T, Mizusawa J, Saito N, Kanemitsu Y, Takiguchi N, et al. Randomised phase III trial of adjuvant chemotherapy with oral uracil and tegafur plus leucovorin versus intravenous fluorouracil and levofolinate in patients with stage III colorectal cancer who have undergone Japanese D2/D3 lymph node dissection: final results of JCOG0205. Eur J Cancer. 2014;50:2231–40.

    Article  CAS  Google Scholar 

  13. Lembersky BC, Wieand HS, Petrelli NJ, O’Connell MJ, Colangelo LH, Smith RE, et al. Oral uracil and tegafur plus leucovorin compared with intravenous fluorouracil and leucovorin in stage II and III carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project Protocol C-06. J Clin Oncol. 2006;24:2059–64.

    Article  CAS  Google Scholar 

  14. Chalasani NP, Hayashi PH, Bonkovsky HL, Navarro VJ, Lee WM, Fontana RJ, et al. ACG clinical guideline: the diagnosis and management of idiosyncratic drug-induced liver injury. Am J Gastroenterol. 2014;109:950–66 quiz 67.

    Article  Google Scholar 

  15. Danan G, Teschke R. RUCAM in drug and herb induced liver injury: the update. Int J Mol Sci. 2015;17.

    Article  Google Scholar 

  16. Institute NC. Common terminology criteria for adverse events (CTCAE) version 5.0. In.

  17. Baba M, Shima T, Tanaka T, Nakayabu M, Hasegawa H, Suzuki S, et al. A case of allergic liver injury induced by tegafur. J Gastroenterol. 1994;29:88–92.

    Article  CAS  Google Scholar 

  18. Kobayashi F, Ikeda T, Sakamoto N, Kurosaki M, Tozuka S, Sakamoto S, et al. Severe chronic active hepatitis induced by UFTR containing tegafur and uracil. Dig Dis Sci. 1995;40:2434–7.

    Article  CAS  Google Scholar 

  19. Maruyama S, Hirayama C, Abe J, Tanaka J, Matsui K. Chronic active hepatitis and liver cirrhosis in association with combined tamoxifen/tegafur adjuvant therapy. Dig Dis Sci. 1995;40:2602–7.

    Article  CAS  Google Scholar 

  20. Matsumoto M, Nakao K, Matsumoto H, Iwata K, Ohta Y, Kanai K, et al. Chronic liver failure induced by long-term administration of tegafur: a case report. Hepatogastroenterology. 1998;45:2372–5.

    CAS  PubMed  Google Scholar 

  21. Akiyama T, Hayashi H, Matsuyama T, Nomura A. Severe multiple organ damage by uracil-tegafur in stage IB lung cancer. Cancer Science: Open Access. 2017;3.

  22. Reuben A, Koch DG, Lee WM, Acute Liver Failure Study G. Drug-induced acute liver failure: results of a U.S. multicenter, prospective study. Hepatology. 2010;52:2065–76.

    Article  Google Scholar 

  23. Lee WM. Drug-induced acute liver failure. Clin Liver Dis. 2013;17:575–86 viii.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Surgery, Saga Medical Center Koseikan, 400 Nakabaru, Kasemachi, Saga City, Saga, 849-8571, Japan

    Masatsugu Hiraki, Toshiya Tanaka, Osamu Ikeda, Atsushi Miyoshi, Kenji Kitahara & Seiji Sato

  2. Department of Hepatobiliary and Pancreatology, Saga Medical Center Koseikan, 400 Nakabaru, Kasemachi, Saga City, Saga, 849-8571, Japan

    Futa Koga & Noriko Oza

  3. Saito Clinic, 214 Odo Morodomi, Saga City, Saga, 840-2101, Japan

    Akimasa Saito

  4. Department of Surgery, Faculty of Medicine, Saga University, 5-1-1 Nabeshima, Saga City, Saga, 849-8501, Japan

    Tatsuya Manabe & Hirokazu Noshiro

Authors
  1. Masatsugu Hiraki
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Toshiya Tanaka
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Futa Koga
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Akimasa Saito
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Noriko Oza
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Osamu Ikeda
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Tatsuya Manabe
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Atsushi Miyoshi
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Kenji Kitahara
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Seiji Sato
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Hirokazu Noshiro
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Masatsugu Hiraki.

Ethics declarations

Conflict of Interest

The authors declare that they have no competing interests.

Research Involving Human Participants and/or Animals

This case report is not a research study. That is not applicable in this case report.

Informed Consent

The patient provided his written informed consent for the publication of this case report and any accompanying images.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Hiraki, M., Tanaka, T., Koga, F. et al. An Unusual Case of Acute Liver Failure Caused by Adjuvant Oral Tegafur-Uracil with Folinate Therapy for Colon Cancer Patient: a Case Report. J Gastrointest Canc 51, 296–299 (2020). https://doi.org/10.1007/s12029-019-00228-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12029-019-00228-7

Search

Navigation